Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sonolisib - Cascadian Therapeutics

Drug Profile

Sonolisib - Cascadian Therapeutics

Alternative Names: PX-866

Latest Information Update: 19 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator The Burnham Institute; University of Arizona; University of Pittsburgh
  • Developer Cascadian Therapeutics; Oncothyreon
  • Class Antineoplastics; Gonanes; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Colorectal cancer; Glioblastoma; Head and neck cancer; Idiopathic pulmonary fibrosis; Malignant melanoma; Non-small cell lung cancer; Prostate cancer; Solid tumours

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 15 Feb 2015 Oncothyreon and NCIC Clinical Trials Group, Canada completes a phase II trial in Glioblastoma (Recurrent, Second-line therapy or greater) in Canada (NCT01259869)
  • 13 Mar 2014 Oncothyreon completes phase I portion of a phase I/II trial in Malignant melanoma (combination therapy) in USA (NCT01616199)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top